Natural Product (NP) Details

General Information of the NP (ID: NP5407)
Name
Moxonidine
Synonyms
MOXONIDINE; 75438-57-2; Norcynt; Nucynt; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine; Cynt; Physiotens; BE 5895; BDF5895; UNII-CC6X0L40GW; BDF 5895; Lomox; 4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine; LY 326869; 4-chloro-N-imidazolidin-2-ylidene-6-methoxy-2-methylpyrimidin-5-amine; CC6X0L40GW; CHEMBL19236; CHEBI:7009; BDF5896; 4-Chloro-5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine; BE-5895; 75438-57-2 (free base); BE5895; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-; NCGC00015649-02; LY326869; Normoxocin; CAS-75438-57-2; DSSTox_CID_25170; DSSTox_RID_80720; DSSTox_GSID_45170; Moxonidinum [Latin]; Moxonidina [Spanish]; Moxonidina; Moxonidinum; 4-chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine; Moxonidine hydrochloride hydrate; BDF-5895; LY-326869; Moxonidine [USAN:INN:BAN]; N-(4-chloro-6-methoxy-2-methylpyrimidin-5-yl)imidazolidin-2-imine; SR-01000075981; Cynt (TN); Moxonidine (USAN/INN); Prestwick0_001016; Prestwick1_001016; Prestwick2_001016; Prestwick3_001016; Lopac-M-1559; Monoxidine [common misspelling of Moxonidine]; Lopac0_000753; SCHEMBL49143; BSPBio_001171; MLS002222183; SPBio_003042; BPBio1_001289; DTXSID5045170; HMS1571K13; HMS2098K13; HMS2230B15; HMS3373O04; HMS3655B17; HMS3715K13; HMS3747A03; Moxonidine 1.0 mg/ml in Methanol; ALBB-022451; BCP23003; BDF-5896; EX-A3409; HY-B0374; ZINC1854466; Tox21_110190; 2-(6-Chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline; 4-Chloro-5-(2-imidazolidinyldeneamino)-6-methoxy-2-methylpyrimidine; 4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine; AC-637; BDBM50050093; KM1693; MFCD22689455; PDSP1_000177; PDSP2_000176; s2066; STL419983; STL450991; AKOS015895873; AKOS015997932; Tox21_110190_1; AF-0062; CCG-204838; DB09242; SDCCGSBI-0050731.P002; VA11330; NCGC00015649-01; NCGC00015649-04; NCGC00015649-05; NCGC00015649-08; NCGC00015649-17; NCGC00092355-02; AK163649; K289; SMR000857402; AB0014143; AB00514003; FT-0601601; FT-0657360; M2660; SW196502-4; T5483; C07451; D05087; AB00514003-08; AB00514003_10; 102678-EP2272841A1; 102678-EP2301936A1; 438M572; Q419944; SR-01000075981-7; BRD-K77771411-001-04-4; (4-Chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine; 4-chloro-N-(imidazolin-2-ylidene)-6-methoxy-2-methyl-5-pyrimidinamine; 5-pyrimidinamine, 4-chloro-N-2-imidazolidinylidene-6-methoxy-2-methyl-; BDF5895;BDF-5895;BDF 5895;BE 5895; BE-5895; BE5895; 2-(4-Chloro-6-methoxy-2-methyl-pyrimidin-5-ylamino)-4,5-dihydro-3H-imidazol-1-ium; 5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- (9CI); (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid; 1008754-16-2
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Substance abuse [ICD-11: 6C40] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C9H12ClN5O
PubChem CID
4810
Canonical SMILES
CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
InChI
1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
InChIKey
WPNJAUFVNXKLIM-UHFFFAOYSA-N
CAS Number
CAS 75438-57-2
ChEBI ID
CHEBI:7009
TTD Drug ID
D0E9PK
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Hydrochlorothiazide      Hypertension     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 This profile of moxonidine is highly comparable to a standard first-line antihypertensive drug such as hydrochlorothiazide, without sacrificing tolerance and safety for increased efficacy, in combination with hydrochlorothiazide.
Target and Pathway
Target(s) Adrenergic receptor alpha-2A (ADRA2A)  Molecule Info  [3]
Adrenergic receptor alpha-2B (ADRA2B)  Molecule Info  [3]
Adrenergic receptor alpha-2C (ADRA2C)  Molecule Info  [3]
KEGG Pathway cGMP-PKG signaling pathway Click to Show/Hide
2 Neuroactive ligand-receptor interaction
Panther Pathway Alpha adrenergic receptor signaling pathway Click to Show/Hide
2 Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Reactome Adrenoceptors Click to Show/Hide
2 Adrenaline signalling through Alpha-2 adrenergic receptor
3 Adrenaline,noradrenaline inhibits insulin secretion
4 G alpha (i) signalling events
5 G alpha (z) signalling events
6 Surfactant metabolism
WikiPathways Monoamine GPCRs Click to Show/Hide
2 GPCRs, Class A Rhodopsin-like
3 Platelet Aggregation (Plug Formation)
4 Integration of energy metabolism
5 GPCR ligand binding
6 GPCR downstream signaling
References
Reference 1 The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat ... J Pharmacol Exp Ther. 2003 Aug;306(2):646-57.
Reference 2 Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol. 1994;24 Suppl 1:S25-8.
Reference 3 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
 Download Picture         KEGG Link